[1]贾如江,王俊霞,牛广旭.生长因子受体结合蛋白1表达和微血管密度与肝癌临床病理特征的关系[J].新乡医学院学报,2020,37(2):140-143.[doi:10.7683/xxyxyxb.2020.02.009]
　JIA Rujiang,WANG Junxia,NIU Guangxu.Relationship between the expression of growth factor receptor binding protein 1 and microvessel density and clinicopathological features of hepatocellular carcinoma[J].Journal of Xinxiang Medical University,2020,37(2):140-143.[doi:10.7683/xxyxyxb.2020.02.009]
点击复制

生长因子受体结合蛋白1表达和微血管密度与肝癌临床病理特征的关系
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
37
期数:
2020年2
页码:
140-143
栏目:
临床研究
出版日期:
2020-02-05

文章信息/Info

Title:
Relationship between the expression of growth factor receptor binding protein 1 and microvessel density and clinicopathological features of hepatocellular carcinoma
作者:
贾如江; 王俊霞; 牛广旭
（邯郸市中心医院普外科，河北　邯郸　056001）
Author(s):
JIA Rujiang; WANG Junxia; NIU Guangxu
(Department of General Surgery,Handan Central Hospital,Handan 056001,Hebei Province,China)
关键词:
肝癌; 生长因子受体结合蛋白1; 免疫组织化学; 血小板内皮黏附分子34; 微血管密度
Keywords:
hepatocellular carcinoma; growth factor receptor binding protein-associated binder1; immunohistochemistry; platelet endothelial adhesion molecule 34; microvessel density
分类号:
R735.7
DOI:
10.7683/xxyxyxb.2020.02.009
文献标志码:
A
摘要:
目的　探讨肝癌组织中生长因子受体结合蛋白1（Gab1）表达和微血管密度(MVD)及其与临床病理特征的关系。方法　选择2014年1月至2016年12月邯郸市中心医院40例肝癌患者手术切除的癌组织标本和其中10例癌旁组织标本为研究对象。采用免疫组织化学法检测肝癌组织和癌旁组织中Gab1和血小板内皮黏附分子34（CD34）的表达，并以CD34在肝癌组织和癌旁组织中的表达值作为MVD，分析其与临床病理学特征的关系。结果　肝癌组织和癌旁组织中Gab1阳性表达率分别为47.5%（19/40）和10.0%（1/10）；肝癌组织中Gab1阳性表达率高于癌旁组织（χ2=10.040，P<0.05）。肝癌组织和癌旁组织中MVD分别为33.72±5.20和8.57±4.35；肝癌组织中MVD高于癌旁组织（P<0.05）。肝癌组织中Gab1的表达与患者的性别、年龄、乙型肝炎病毒无相关性（P>0.05），而与肿瘤组织分化程度、肿瘤大小、肿瘤分期、门静脉癌栓、甲胎蛋白（AFP）水平显著相关（P<0.05）。MVD与肿瘤大小、肿瘤分期、门静脉癌栓显著相关（P<0.05），与患者的性别、年龄、乙型肝炎病毒、肿瘤组织分化程度及AFP水平无相关性（P>0.05）。结论　肝癌组织中Gab1表达和MVD高于癌旁组织，且与肝癌分期、肿瘤大小、门静脉癌栓、AFP水平有关。
Abstract:
Objective　To study the expression of growth factor receptor binding protein 1(Gab1) and microvessel density(MVD) in hepatocellular carcinoma and their relationship with clinicopathological features.Methods　From January 2014 to December 2016,40 specimens of liver cancer tissue and 10 specimens of paracancerous tissues were selected from Handan Central Hospital.The expression of Gab1 protein and platelet endothelial adhesion molecule 34 (CD34) in liver cancer tissue and paracancerous tissue were detected by immunohistochemistry.The expression of platelet endothelial adhesion molecule 34 (CD34) in liver cancer tissues and paracancerous tissues was used as MVD level.The relationship between Gab1 protein expression,MVD and clinicopathological features were analyzed.Results　The positive expression rates of Gab1 protein in hepatocellular carcinoma tissues and paracancerous tissues were 47.5%（19/40） and 10.0%（1/10）,respectively,and the positive expression rates of Gab1 protein in hepatocellular carcinoma tissues were higher than those in paracancerous tissues (χ2=10.040，P<0.05).The MVD in hepatocellular carcinoma tissues and paracancerous tissues were 33.72±5.20 and 8.57±4.35,respectively.The MVD in hepatocellular carcinoma tissues was higher than that in the paracancerous tissues (P<0.05).The expression of Gab1 protein in hepatocellular carcinoma tissue was not correlated with the sex,age of patients and hepatitis B virus（P>0.05）,but it was significantly correlated with differentiation degree of tumor,tumor size,tumor stage,portal vein thromboembolism,and alpha-fetoprotein (AFP) level (P<0.05).MVD was significantly correlated with tumor size,tumor staging and portal vein thromboembolism (P<0.05),but it was not correlated with gender,age,hepatitis B virus,differentiation degree of tumor and AFP expression (P>0.05).Conclusions　The expression of Gab1 protein and MVD in hepatocellular carcinoma tissues is significantly higher than that in adjacent tissues.They have synergistic effects and are related to the stage of hepatocellular carcinoma,the size of tumors,the expression of portal vein thrombus and AFP.

参考文献/References:

［1］　温庆良,黄煜庆,葛明华.Gab1在恶性肿瘤中的研究进展［J］.中国肿瘤,2017,26（1）：53-57.
［2］　EROGLU A,ERSOZ C,KARASOY D,et al．Vascular endothelial growth factor-C,VEGF-D,VEGFR-3 and D2-40 expressions in primary breast cancer:association with lymph node metastasis［J］.Adv Clin Exp Med,2017,26(2):245-249.
［3］　NAIKOON A,AFROZE D,RASOOL R,et al.SNP and haplotype analysis of vascular endothelial growth factor(VEGF)gene in lung cancer patients of kashmir［J］.Asian Pac J Cancer Prev,2017,18(7):1799-1804.
［4］　SAKATA N，AOKI T，YOSHIMATSU G，et al.Strategy for clinical setting in intramuscular and subcutaneous islet transplantation［J］.Diabetes Metab Res Rev，2014，30 （1） ：1-10.
［5］　李巧,华赘鹏,吉斐,等.第8版AJCC肝细胞癌分期系统对可切除肝癌患者预后评估的价值［J］.中华普通外科杂志,2018,33(3):208-213.
［6］　DENG R,ZHAO X,QU Y,et al.Shp2 SUMO ylation promotes ERK activation and hepatocellular carcinoma development［J］.Oncotarge，2015,6(11):9355-9369.
［7］　WANG J,SONG W,SHEN W,et al.MicroRNA-200a suppresses cell invasion and migration by directly targeting GAB1 in hepatocellular carcinoma［J］.Oncol Res，2017,25(1):1-10.
［8］　HOEBEN A,MARTIN D,CLEMENT P M,et al.Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma［J］.Int J Cancer,2013,132(5):1042-1050.
［9］　FAN Y X,WONG L,MARINO M P,et al.Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants［J］.J Biol Chem,2013,288(23):16895-16904.
［10］　SUN W,ZHANG Z,WANG J,et al.MicroRNA-150 suppresses cell proliferation and metastasis in hepatocellular carcinoma by inhibiting the GAB1-ERK axis［J］.Oncotarget，2016,7(10):11595-11608.
［11］　DAI L,PENG X X,TAN EM,et al．Tumor-associated antigen CAPERa and microvessel density in hepatocellular carcinoma［J］．Oncotarget，2016，32(5)：90.
［12］　MUTO J,SHIRABE K,SUGIMACHI K,et al.Review of angiogenesis in hepatocellular carcinoma［J］.Hepatol Res，2015，45（1）：1-9.
［13］　MURAKAMI K，KASAJIMA A，KAWAGISHI N，et al.Microvessel density in hepatocellular carcinoma：prognostic significance and review of the previous published work［J］.Hepatol Res，2015，45（12）：1185-1194.
［14］　LUO Q，ZHANG Y，WANG N，et al．Leukemia inhibitory factor receptor is a novel immunomarker in distinction of well．differentiated HCC from dysplastic nodules［J］．Oncotarget，2015，6(9)：6989-6999．
［15］　SHIOYAMA W,NAKAOKA Y,HIGUCHI K,et al.Docking protein Gab1 is an essential component of postnatal angiogenesis after ischemia via HGF/c-met signaling ［J］.Circ Res,2011,108(6):664 -675.
［15］　吴黎明,陈先祥,程彩涛,等.CD133和VEGF在肝细胞癌表达及其预后预测价值［J］.中国肝脏病杂志,2013,5(1):37-41.

相似文献/References:

[1]王克霞,张荣波,唐小龙,等.肝细胞性肝癌与乙型肝炎病毒感染相关性的研究[J].新乡医学院学报,1997,14(03):281.
[2]杨瑞民,张凯,李玉侠,等.巨块型肝癌肝动脉栓塞后无水酒精注射疗效观察[J].新乡医学院学报,1997,14(04):382.
[3]甄艳华,杨利霞.肝癌患者肝动脉血流动力学的彩色多普勒研究[J].新乡医学院学报,2008,25(01):062.
[4]沈洁,阮健,郑航,等.ZD6474对肝癌HepG2细胞的抑制作用[J].新乡医学院学报,2010,27(03):234.
[5]黄长山,余伟,王云检,等.外科Apgar评分在肝癌术后并发症预测中的应用 TitleFilter('chTitle');[J].新乡医学院学报,2010,27(04):365.
[6]孙春伟,吴广银.哺乳动物雷帕霉素靶蛋白对肝癌细胞系Hep3B中侧群细胞的影响[J].新乡医学院学报,2011,28(03):307.
[7]王　雷１,王煜霞２,薛会朝１. 肝癌患者肿瘤坏死因子α和白细胞介素８水平变化及其与临床病理特征的关系[J].新乡医学院学报,2015,32(08):735.
[8]罗羽田,李世朋,徐红伟,等.铁死亡在肝癌中的调控机制及作用研究进展[J].新乡医学院学报,2021,38(1):091.[doi:10.7683/xxyxyxb.2021.01.020]
[9]王政强,韩锋博.肝癌切除术联合肝动脉化疗栓塞术治疗中晚期肝癌疗效观察[J].新乡医学院学报,2021,38(10):957.[doi:10.7683/xxyxyxb.2021.10.012]
　WANG Zhengqiang,HAN Fengbo.Effect of hepatectomy combined with transcatheter hepatic arterial chemoembolization in the treatment of middle-advanced liver cancer[J].Journal of Xinxiang Medical University,2021,38(2):957.[doi:10.7683/xxyxyxb.2021.10.012]
[10]李　妍,朱绍辉,张　彬.肝癌患者肝切除术后感染性并发症的相关危险因素分析[J].新乡医学院学报,2016,33(9):767.[doi:10.7683/xxyxyxb.2016.09.007]
　LI Yan,ZHU Shao-hui,ZHANG Bin.Analysis of the risk factors for infectious complications in patients with hepatocellular carcinoma after hepatectomy[J].Journal of Xinxiang Medical University,2016,33(2):767.[doi:10.7683/xxyxyxb.2016.09.007]

更新日期/Last Update: 2020-02-05